相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes
Amy S. Etheridge et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients
F. Innocenti et al.
EUROPEAN JOURNAL OF CANCER (2020)
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)
Federico Innocenti et al.
PHARMACOGENETICS AND GENOMICS (2019)
Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
Racheal G. Akwii et al.
CELLS (2019)
Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer
Deok-Hoon Kong et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
Megan Li et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Genetic variation determines VEGF-A plasma levels in cancer patients
Federico Innocenti et al.
SCIENTIFIC REPORTS (2018)
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Daniel L. Hertz et al.
CLINICAL CANCER RESEARCH (2016)
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Ace J. Hatch et al.
CANCER MEDICINE (2016)
New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide
W. van Boxtel et al.
BIOMARKERS (2015)
Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
Bonnie Ky et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
Yingmiao Liu et al.
CANCER MEDICINE (2014)
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Andrew B. Nixon et al.
CLINICAL CANCER RESEARCH (2013)
Interrelationships between the concentration and size of the largest high-density lipoprotein subfraction and apolipoprotein C-I in infants at birth and follow-up at 2-3 months of age and their parents
Peter O. Kwiterovich et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2013)
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
Yingmiao Liu et al.
CANCER MEDICINE (2013)
A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
Federico Innocenti et al.
CLINICAL CANCER RESEARCH (2012)
Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies
Patrizia Ferroni et al.
CURRENT VASCULAR PHARMACOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations
Mathew J. Barber et al.
PLOS ONE (2010)
Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin
Sascha David et al.
JOURNAL OF HYPERTENSION (2009)
The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia
Eun Sung Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2007)
Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice
V. Schmitz et al.
GENE THERAPY (2006)
Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]
SK Nadar et al.
JOURNAL OF INTERNAL MEDICINE (2005)
Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension
WC Tsai et al.
CLINICAL SCIENCE (2005)
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G Bocci et al.
CANCER RESEARCH (2004)
Patients with essential hypertension present higher levels of sE-selectin and sVCAM-1 than normotensive volunteers
I Palomo et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2003)
How a damaged blood vessel wall contibutes to thrombosis and hypertension
AD Blann
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo
IB Lobov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease
TD Henry et al.
AMERICAN HEART JOURNAL (2001)
Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension
FM Belgore et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells
I Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood
E Gunsilius et al.
ONCOLOGY (2000)
分享论文
